Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation

Journal of Medical Virology

Volumn 80, Issue 3, 2008, Pages 478-483

  Hiller, Thomas ^a   Stubenrauch, Frank ^a   Iftner, Thomas ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

E6 protein; HPV; p53; Risk classification; Variants

Indexed keywords

AMINO ACID; PROTEIN E6; PROTEIN E7; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENICITY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPR 56; IMMUNE SYSTEM; INVASIVE CARCINOMA; NONHUMAN; PERSISTENT VIRUS INFECTION; PROTEIN DEGRADATION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; RISK FACTOR; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE; VIRUS ISOLATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PLASMIDS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

HUMAN PAPILLOMAVIRUS;

EID: 38849194749     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21093     Document Type: Article

References (48)

1. Alvarez-Salas LWS, Burger R, Monk B, Dipaolo J. 1995. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int J Oncol 7:261-266.
2. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. 2000. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 74:11636-11641.
3. Arias-Pulido H, Joste N, Wheeler CM. 2004. Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. Genes Chromosomes Cancer 40:277-284.
4. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A. 2001. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: A case-control study. J Natl Cancer Inst 93:1325-1330.
5. Beskow AH, Gyllensten UB. 2002. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 101:526-531.
6. Beskow AH, Josefsson AM, Gyllensten UB. 2001. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 93:817-822.
7. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
8. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Schwartz P, Glass A, Hildesheim A. 2005. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201:1069-1075.
9. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S. 2004. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 78:5934-5945.
10. Chan SY, Delius H, Halpern AL, Bernard HU. 1995. Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy. J Virol 69:3074-3083.
11. Chaturvedi AK, Brinkman JA, Gaffga AM, Dumestre J, Clark RA, Braly PS, Dunlap K, Kissinger PJ, Hagensee ME. 2004. Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women. J Gen Virol 85:1237-1241.
12. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol 6:204.
13. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM. 2002. Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J Infect Dis 185:1229-1237.
14. de Villiers EM. 1989. Heterogeneity of the human papillomavirus group. J Virol 63:4898-4903.
15. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
16. del Refugio Gonzalez-Losa M, Laviada Mier y Teran MA, Puerto-Solis M, Garcia-Carranca A. 2004. Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. J Clin Virol 29:95-98.
17. Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, et al. 1995. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1:464-470.
18. Gardiol D, Kuhne C, Glaunsinger B, Lee SS, Javier R, Banks L. 1999. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18:5487-5496.
19. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. 2000. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19:5270-5280.
20. Grodzki M, Besson G, Clavel C, Arslan A, Franceschi S, Birembaut P, Tommasino M, Zehbe I. 2006. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev 15:820-822.
21. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191:1796-1807.
22. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. 2006. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 15:1262-1267.
23. Lichtig H, Algrisi M, Botzer LE, Abadi T, Verbitzky Y, Jackman A, Tommasino M, Zehbe I, Sherman L. 2006. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350:216-227.
24. Lizano M, Berumen J, Guido MC, Casas L, Garcia-Carranca A. 1997. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 89:1227-1231.
25. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. 1996. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69:364-368.
26. Mansour M, Touka M, Hasan U, Bellopede A, Smet A, Accardi R, Gabet AS, Sylla BS, Tommasino M. 2007. E7 properties of mucosal human papillomavirus types 26,53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 367:1-9.
27. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
28. Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M. 1999. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 82:203-207.
29. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. 2003. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8466 patients. Br J Cancer 88:1570-1577.
30. Picconi MA, Alonio LV, Sichero L, Mbayed V, Villa LL, Gronda J, Campos R, Teyssie A. 2003. Human papillomavirus type-16 variants in Quechua aboriginals from Argentina. J Med Virol 69:546-552.
31. Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Ortiz-Lopez R, Barrera-Saldana HA, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Sanchez GI, Bosch FX, Villa LL. 2005. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 340:95-104.
32. Radhakrishna Pillai M, Sreevidya S, Pollock BH, Jayaprakash PG, Herman B. 2002. Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer. Gynecol Oncol 87:268-273.
33. Sathish N, Abraham P, Peedicayil A, Sridharan G, Chandy G. 2005. HPV 16 E6 sequence variations in Indian patients with cervical neoplasia. Cancer Lett 229:93-99.
34. Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. 1996. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 70:6987-6993.
35. Thomas M, Glaunsinger B, Pim D, Javier R, Banks L. 2001. HPV E6 and MAGUK protein interactions: Determination of the molecular basis for specific protein recognition and degradation. Oncogene 20:5431-5439.
36. van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Helmerhorst TJ, Meijer CJ, Walboomers JM. 2000. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81:317-325.
37. Veress G, Szarka K, Dong XP, Gergely L, Pfister H. 1999. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J Gen Virol 80:1035-1043.
38. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. 2000. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 81:2959-2968.
39. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
40. Wheeler CM, Yamada T, Hildesheim A, Jenison SA. 1997. Human papillomavirus type 16 sequence variants: Identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol 35:11-19.
41. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, Holmes KK, Galloway DA. 1995. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 172:747-755.
42. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, Holmes KK, Kiviat NB. 1997. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 89:796-802.
43. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. 1995. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69:7743-7753.
44. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. 1997. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. J Virol 71:2463-2472.
45. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. 1998a. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352:1441-1442.
46. Zehbe I, Wilander E, Delius H, Tommasino M. 1998b. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833.
47. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. 2001. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 94:711-716.
48. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. 2003. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 64:538-542.